This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look: Discussing atezolizumab and lurbinectedin in 1L ES-SCLC (IMforte trial)
Ticker(s): JAZZWho's the expert?
- Medicial Oncologist with specialties in Hematology, Breast Cancer, Lymphoma & Chronic Leukemia, Multiple Myeloma, Lung & Thoracic Cancers
- Directed the hematology/oncology fellowship training program at the Cleveland Clinic.
- Extensive research expertise in the laboratory and clinical trials with the pharmaceutical industry and leading academic institutions
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
